MedTrace Logo

Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix®

NCT06184204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398

Last updated 2025-09-19

No results posted yet for this study

Summary

The rational behind this observational study is to collect real life data about the use of Trombix® (Rivaroxaban) among patients with atrial fibrillation in Algeria . The aim is to evaluate the safety, efficacy and quality of life.

Conditions

Interventions

DRUG

Trombix® (Rivaroxaban)

20mg or 15 mg as per the doctor's prescription

Sponsors & Collaborators

  • Beker Laboratories

    lead INDUSTRY

Principal Investigators

  • Pr Aoudia Yazid · EPH Tipaza

  • Pr ADJEROUD Naima · Faculty of Medicine of Algiers

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2025-03-30
Completion
2025-06-22

Countries

  • Algeria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184204 on ClinicalTrials.gov